Hydroxychloroquine in SARS-CoV-2 infection: Understanding the misadventure

Abstract

The widespread outbreak of SARS-CoV-2 was declared a public health emergency by the World Health Organization and various governments worldwide. This prompted the implementation of stringent infection control measures to curb the spread of the virus. Amidst this, the medical community faced the challenge of treating the virus without specific therapies or a vaccine, leading to reliance on empirical treatment approaches. In this context, hydroxychloroquine, an antimalarial and antirheumatic drug, gained attention as a potential treatment option. Despite its theoretical benefits, such as inhibiting viral entry, reducing inflammation, and modulating immune responses, empirical studies yielded inconsistent results. Some indicated a potential for symptom relief, while others showed no significant improvement in patient outcomes. The initial enthusiasm waned as the lack of substantial evidence led to revoking its Emergency Use Authorization, and several clinical trials were prematurely halted. The review in question critically examines the factors contributing to the ineffectiveness of hydroxychloroquine in treating SARS-CoV-2 infection, highlighting the complexities of drug repurposing during a rapidly evolving pandemic.

Keywords

SARS-CoV-2 / Hydroxychloroquine / Pharmacogenomics / TLR signaling / Cardiotoxicity

References

[1] WHO. COVID—19 dashboard. [Online] Available from: https://data.who.int/dashboards/covid19/cases?n=c [Accessed on April 3, 2024].

[2] Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS—CoV—2) and coronavirus disease—2019 (COVID—19): The epidemic and the challenges. Int J Antimicrob Agents 2020; 55(3): 105924.

[3] Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020; 14(1): 64-68.

[4] Pastick KA, Okafor EC, Wang F, Lofgren SM, Skipper CP, Nicol MR, et al. Hydroxychloroquine and chloroquine for treatment of SARS—CoV—2 (COVID—19). Open Forum Infect Dis 2020; 7(4): ofaa130.

[5] Morawski PA, Bolland S. Expanding the B cell centric view of systemic lupus erythematosus. Trends Immunol 2017; 38(5): 373-382.

[6] Boulos A, Rolain JM, Raoult D. Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells. Antimicrob Agents Chemother 2004; 48(3): 747.

[7] Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 2007; 30(4): 297-308.

[8] FDA U. Coronavirus (COVID—19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. [Online] Available from: https://fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and [Accessed on November 15, 2020].

[9] WHO. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID—19. [Online] Available from: www.who.int/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19 [Accessed on November 15, 2020].

[10] Gov.UK. MHRA suspends recruitment to COVID—19 hydroxychloroquine trials. [Online] Available from: www.gov.uk/government/news/mhra-suspends-recruitment-to-covid-19-hydroxychloroquine-trials [Accessed on November 15, 2020].

[11] National Institute of Health Research N. Case study: The UK’s flagship COVID—19 treatment trial — the RECOVERY trial. [Online] Available from: www.nihr.ac.uk/case-studies/the-uks-flagship-covid-19-treatment-trial-the-recovery-trial/25358 [Accessed on November 15, 2020].

[12] ClinicalTrials.gov. Assessing hydroxychloroquine in patients with SARS—CoV—2 (COVID—19). [Online] Available from: www.clinicaltrials.gov/ct2/show/NCT04363866?cond=hydroxychloroquine+for+covid—19&draw=5 [Accessed on November 13, 2020].

[13] ClinicalTrials.gov. Chloroquine/Hydroxychloroquine prevention of coronavirus disease (COVID—19) in the healthcare setting (COPCOV). [Online] Available from: https://clinicaltrials.gov/ct2/show/NCT04303507 [Accessed on November 13, 2020].

[14] Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS—CoV—2). Clin Infect Dis 2020; 71(15): 732-739.

[15] Braun S, Ferner M, Kronfeld K, Griese M. Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases. Pediatr Pulmonol 2015; 50(4): 410-419.

[16] Tett SE, Cutler DJ, Beck C, Day RO. Concentration—effect relationship of hydroxychloroquine in patients with rheumatoid arthritis——A prospective, dose ranging study. J Rheumatol 2000; 27(7): 1656-1660.

[17] Catteau L, Dauby N, Montourcy M, Bottieau E, Hautekiet J, Goetghebeur E, et al. Low—dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID—19: A nationwide observational study of 8 075 participants. Int J Antimicrob Agents 2020; 56(4): 106144.

[18] Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID—19. Int J Antimicrob Agents 2020: 105932.

[19] Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS—CoV—2 infection in vitro. Cell Discov 2020; 6: 16.

[20] De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther 2006; 4(2): 291-302.

[21] Meyerowitz EA, Vannier AG, Friesen MG, Schoenfeld S, Gelfand JA, Callahan MV, et al. Rethinking the role of hydroxychloroquine in the treatment of COVID—19. FASEB J 2020; 34(5): 6027-6037.

[22] Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ. Hydroxychloroquine inhibits calcium signals in T cells: A new mechanism to explain its immunomodulatory properties. Blood 2000; 95(11): 3460-3466.

[23] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID—19 in Wuhan, China: A retrospective cohort study. Lancet 2020; 395(10229): 1054-1062.

[24] Nicastri E, Petrosillo N, Ascoli Bartoli T, Lepore L, Mondi A, Palmieri F, et al. National institute for the infectious diseases “L. spallanzani”, IRCCS. Recommendations for COVID—19 clinical management. Infect Dis Rep 2020; 12: 8543.

[25] Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without azithromycin in mild—to—moderate COVID—19. New Engl J Med 2020. PMID: 32706953.

[26] Molina JM, Delaugerre C, Le Goff J, Mela—Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID—19 infection. Med Mal Infect 2020; 50(4): 384.

[27] Mahévas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with COVID—19 pneumonia who require oxygen: Observational comparative study using routine care data. BMJ 2020; 369: m1844.

[28] Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID—19. New Engl J Med 2020; 383(6): 517-525.

[29] Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019—nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020; 63(3): 364-374.

[30] Shete A, Urgent need for evaluating agonists of angiotensin—(1—7)/Mas receptor axis for treating patients with COVID—19. Int J Infect Dis 2020; 96: 348-351.

[31] Nabah YNA, Mateo T, Estellés R, Mata M, Zagorski J, Sarau H, et al. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 2004; 110(23): 3581-3586.

[32] Senchenkova EY, Russell J, Almeida—Paula LD, Harding JW, Granger DN. Angiotensin II—mediated microvascular thrombosis. Hypertension 2010; 56(6): 1089-1095.

[33] Sieńko JK, Bogacz A, Lechowicz K, Drożdżal S, Rosik J, Sietnicki M, et al. COVID—19: The influence of ACE genotype and ACE—I and ARBs on the course of SARS—CoV—2 infection in elderly patients. Clin Interv Aging 2020; 15: 1231-1240.

[34] Copetti T, Bertoli C, Dalla E, Demarchi F, Schneider C. p65/RelA modulates BECN1 transcription and autophagy. Mol Cell Biol 2009; 29(10): 2594-2608.

[35] Trocoli A, Djavaheri—Mergny M. The complex interplay between autophagy and NF—kappaB signaling pathways in cancer cells. Am J Cancer Res 2011; 1(5): 629-649.

[36] Teijaro JR. Type I interferons in viral control and immune regulation. Curr Opin Virol 2016; 16: 31-40.

[37] Hipp M, Shepherd D, Gileadi U, Aichinger M, Kessler B, Edelmann M, et al. Processing of human toll—like receptor 7 by furin—like proprotein convertases is required for its accumulation and activity in endosomes. Immunity 2013; 39: 711-721.

[38] Simon S, Roy D, Schindler M. Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci U S A 1994; 91(3): 1128-1132.

[39] Lin CW, Tsai FJ, Wan L, Lai CC, Lin KH, Hsieh TH, et al. Binding interaction of SARS coronavirus 3CL(pro) protease with vacuolar—H⁺ ATPase G1 subunit . FEBS Lett 2005; 579(27): 6089-6094.

[40] Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, et al. Trained immunity: A program of innate immune memory in health and disease. Science 2016; 352(6284): aaf1098.

[41] Mitroulis I, Ruppova K, Wang B, Chen LS, Grzybek M, Grinenko T, et al. Modulation of myelopoiesis progenitors is an integral component of trained immunity. Cell 2018; 172(1—2): 147-161.e12.

[42] Yao Y, Jeyanathan M, Haddadi S, Barra NG, Vaseghi—Shanjani M, Damjanovic D, et al. Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity. Cell 2018; 175(6): 1634-1650.e17.

[43] O’Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo—starvation. Nature 2013; 493(7432): 346-355.

[44] Rother N, Yanginlar C, Lindeboom RGH, Bekkering S, van Leent MMT, Buijsers B, et al. Hydroxychloroquine inhibits trained immunity — implications for COVID—19. medRxiv 2020: 2020.06.08.20122143.

[45] Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002; 71: 537-592.

[46] Zamora JM, Pearce HL, Beck WT. Physical—chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 1988; 33(4): 454-462.

[47] Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138(1): 103-141.

[48] Lee JY, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS, et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients With systemic lupus erythematosus. Arthritis Rheumatol 2016; 68(1): 184-190.

[49] Hersberger M, Marti—Jaun J, Rentsch K, Hanseler E. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra—primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 2000; 46(8 Pt 1): 1072-1077.

[50] Bertilsson L, Dahl ML, Dalén P, Al—Shurbaji A. Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53(2): 111-122.

[51] Takahashi T, Luzum JA, Nicol MR, Jacobson PA, Pharmacogenomics of COVID—19 therapies. NPJ Genomic Med 2020; 5(1): 35.

[52] Lieb W, Graf J, Götz A, König IR, Mayer B, Fischer M, et al. Association of angiotensin—converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy. J Mol Med (Berl) 2006; 84(1): 88-96.

[53] Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: An unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003; 4(4): 224-232.

[54] Jover R, Bort R, Gómez—Lechón MJ, Castell JV. Down—regulation of human CYP3A4 by the inflammatory signal interleukin—6: Molecular mechanism and transcription factors involved. FASEB J 2002; 16(13): 1799-1801.

[55] Zhuang Y, de Vries DE, Xu Z, Marciniak SJ Jr, Chen D, Leon F, et al. Evaluation of disease—mediated therapeutic protein—drug interactions between an anti—interleukin—6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. J Clin Pharmacol 2015; 55(12): 1386-1394.

[56] Mallick P, Taneja G, Moorthy B, Ghose R. Regulation of drug—metabolizing enzymes in infectious and inflammatory disease: Implications for biologics—small molecule drug interactions. Expert Opin Drug Metab Toxicol 2017; 13(6): 605-616.

[57] Hooks M, Bart B, Vardeny O, Westanmo A, Adabag S. Effects of hydroxychloroquine treatment on QT interval. Heart Rhythm 2020; 17(11): 1930-1935.

[58] Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID—19). JAMA Cardiol 2020; 5(9): 1036-1041.

[59] Haugaa KH, Bos JM, Tarrell RF, Morlan BW, Caraballo PJ, Ackerman MJ. Institution—wide QT alert system identifies patients with a high risk of mortality. Mayo Clin Proc 2013; 88(4): 315-325.

[60] Jankelson L, Karam G, Becker ML, Chinitz LA, Tsai MC. QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID—19: A systematic review. Heart Rhythm 2020; 17(9): 1472-1479.

[61] Porta AD, Bornstein K, Coye A, Montrief T, Long B, Parris MA. Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians. Am J Emerg Med 2020; 38(10): 2209-2217.

[62] Smulyan H. The computerized ECG: Friend and foe. Am J Med 2019; 132(2): 153-160.

[63] Schwartz PJ, Woosley RL. Predicting the unpredictable: Drug—induced QT prolongation and Torsades de Pointes. J Am Coll Cardiol 2016; 67(13): 1639-1650.

[64] Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158(11): 1774-1782.

[65] Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351(11): 1089-1096.

[66] Goldstein EJ, Owens RC, jr, Nolin TD. Antimicrobial—associated QT interval prolongation: Pointes of interest. Clin Infect Dis 2006; 43(12): 1603-1611.

[67] Huang BH, Wu CH, Hsia CP, Yin Chen C. Azithromycin—induced torsade de pointes. Pacing Clin Electrophysiol 2007; 30(12): 1579-1582.

[68] Lu ZK, Yuan J, Li M, Sutton SS, Rao GA, Jacob S, et al. Cardiac risks associated with antibiotics: Azithromycin and levofloxacin. Expert Opin Drug Saf 2015; 14(2): 295-303.

[69] Albert RK, Schuller JL, Network CC. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med 2014; 189(10): 1173-1180.

[70] Makunts T, Cohen IV, Awdishu L, Abagyan R. Analysis of postmarketing safety data for proton—pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep 2019; 9(1): 2282.